天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2014年
2期
176-178
,共3页
关节成形术,置换,髋%关节成形术,置换,膝%髋骨折%静脉血栓形成%伤口愈合%依诺肝素%利伐沙班
關節成形術,置換,髖%關節成形術,置換,膝%髖骨摺%靜脈血栓形成%傷口愈閤%依諾肝素%利伐沙班
관절성형술,치환,관%관절성형술,치환,슬%관골절%정맥혈전형성%상구유합%의낙간소%리벌사반
arthroplasty,replacement,hip%arthroplasty,replacement,knee%hip fracture%venous thrombosis%wound healing%enoxaparin%rivaroxaban
目的：评估骨科大手术术后使用利伐沙班（rivaroxaban）或依诺肝素预防深静脉血栓形成（DVT）和肺栓塞（PE）的有效性及安全性。方法自2009年9月-2012年5月共278例接受骨科大手术患者，其中140例（平均年龄72.7岁，42.8％为男性）患者口服利伐沙班，每日10 mg，138例（平均年龄69.9岁，39.1％为男性）患者皮下注射依诺肝素，每日40 mg，将2组对比研究终点事件，包括静脉血栓形成（DVT和PE），出现伤口并发症，再度入院，需要输血，主要的和次要的非手术相关出血事件及死亡。结果利伐沙班组和伊诺肝素组2组间VTE的发病率、输血和再入院率差异无统计学意义，次要出血事件的发生率分别为2.1%和5.8％，伤口并发症发生率分别为2.9％和5.7％，2组均无肺动脉栓塞、严重出血或死亡患者。结论利伐沙班和依诺肝素在VTE或严重出血事件的发生率无明显差异。利伐沙班组在次要出血事件和伤口并发症发生率略低，更为安全。
目的：評估骨科大手術術後使用利伐沙班（rivaroxaban）或依諾肝素預防深靜脈血栓形成（DVT）和肺栓塞（PE）的有效性及安全性。方法自2009年9月-2012年5月共278例接受骨科大手術患者，其中140例（平均年齡72.7歲，42.8％為男性）患者口服利伐沙班，每日10 mg，138例（平均年齡69.9歲，39.1％為男性）患者皮下註射依諾肝素，每日40 mg，將2組對比研究終點事件，包括靜脈血栓形成（DVT和PE），齣現傷口併髮癥，再度入院，需要輸血，主要的和次要的非手術相關齣血事件及死亡。結果利伐沙班組和伊諾肝素組2組間VTE的髮病率、輸血和再入院率差異無統計學意義，次要齣血事件的髮生率分彆為2.1%和5.8％，傷口併髮癥髮生率分彆為2.9％和5.7％，2組均無肺動脈栓塞、嚴重齣血或死亡患者。結論利伐沙班和依諾肝素在VTE或嚴重齣血事件的髮生率無明顯差異。利伐沙班組在次要齣血事件和傷口併髮癥髮生率略低，更為安全。
목적：평고골과대수술술후사용리벌사반（rivaroxaban）혹의낙간소예방심정맥혈전형성（DVT）화폐전새（PE）적유효성급안전성。방법자2009년9월-2012년5월공278례접수골과대수술환자，기중140례（평균년령72.7세，42.8％위남성）환자구복리벌사반，매일10 mg，138례（평균년령69.9세，39.1％위남성）환자피하주사의낙간소，매일40 mg，장2조대비연구종점사건，포괄정맥혈전형성（DVT화PE），출현상구병발증，재도입원，수요수혈，주요적화차요적비수술상관출혈사건급사망。결과리벌사반조화이낙간소조2조간VTE적발병솔、수혈화재입원솔차이무통계학의의，차요출혈사건적발생솔분별위2.1%화5.8％，상구병발증발생솔분별위2.9％화5.7％，2조균무폐동맥전새、엄중출혈혹사망환자。결론리벌사반화의낙간소재VTE혹엄중출혈사건적발생솔무명현차이。리벌사반조재차요출혈사건화상구병발증발생솔략저，경위안전。
Objective To evaluate the effectiveness and safety of rivaroxaban or enoxaparin in preventing deep vein thrombosis(DVT) and pulmonary embolism (PE) after major orthopedic surgery. Methods A total of 278 patients underwent major orthopedic surgery, from September 2009 to May 2012, were included in this study. One hundred and forty patients (the average age was 72.7 years, 42.8% were male) were treated with oral rivaroxaban, 10 mg/d. One hundred and thirty-eight patients (the average age was 69.9 years, 39.1%were male) were treated with subcutaneous enoxaparin,40 mg/d. Data were compared between two groups. The ending events included venous thrombosis VTE(DVT and PE), wound complica-tions, re-admission,need for blood transfusion,big and minor bleeding events and death. Results There were no signifi-cant differences in the incidence of VTE, blood transfusions and re- admission rates between two groups. The incidence rates of minor bleeding were 2.1%and 5.8%in two groups. There were no pulmonary embolism, severe bleeding or death in two groups of patients.Conclusion There were no significant differences in the incidence rates of VTE or major bleeding areas in patients with oral treatment of rivaroxaban and enoxaparin.Rivaroxaban was safer with a slightly decrease in minor bleeding and wound complications.
